Patents by Inventor Brett MALONE

Brett MALONE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180362976
    Abstract: Disclosed are antisense molecules and compositions for the treatment of Staphylococcus aureus infection. The antisense molecules and compositions comprise nucleic acid molecules, such as RNA, DNA, or nucleic acid molecules with modified backbones, such as PNA. The antisense molecules and compositions inhibit gene expression in Staphylococcus aureus; are optionally conjugated to cell penetration molecules such as peptides; and are optionally administered in the form of a nanoparticle composition.
    Type: Application
    Filed: January 3, 2018
    Publication date: December 20, 2018
    Applicant: Techulon Inc.
    Inventors: Brett MALONE, Joshua Bryson
  • Patent number: 9909123
    Abstract: Disclosed are antisense molecules and compositions for the treatment of Staphylococcus aureus infection. The antisense molecules and compositions comprise nucleic acid molecules, such as RNA, DNA, or nucleic acid molecules with modified backbones, such as PNA. The antisense molecules and compositions inhibit gene expression in Staphylococcus aureus; are optionally conjugated to cell penetration molecules such as peptides; and are optionally administered in the form of a nanoparticle composition.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 6, 2018
    Assignee: Techulon Inc.
    Inventors: Brett Malone, Joshua Bryson
  • Patent number: 9777274
    Abstract: Disclosed are antisense molecules and compositions for the treatment of Staphylococcus aureus infection. The antisense molecules and compositions comprise nucleic acid molecules, such as RNA, DNA, or nucleic acid molecules with modified backbones, such as PNA. The antisense molecules and compositions inhibit expression of membrane stability proteins in Staphylococcus aureus; are optionally conjugated to cell penetration molecules such as peptides; and are optionally administered in the form of a nanoparticle composition.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 3, 2017
    Assignee: TECHULON INC.
    Inventors: Brett Malone, Joshua Bryson
  • Publication number: 20160177309
    Abstract: Disclosed are antisense molecules and compositions for the treatment of Staphylococcus aureus infection. The antisense molecules and compositions comprise nucleic acid molecules, such as RNA, DNA, or nucleic acid molecules with modified backbones, such as PNA. The antisense molecules and compositions inhibit expression of membrane stability proteins in Staphyloccoccus aureus; are optionally conjugated to cell penetration molecules such as peptides; and are optionally administered in the form of a nanoparticle composition.
    Type: Application
    Filed: March 14, 2014
    Publication date: June 23, 2016
    Applicant: Techulon Inc.
    Inventors: Brett MALONE, Joshua BRYSON
  • Publication number: 20160177297
    Abstract: Disclosed are antisense molecules and compositions for the treatment of Staphylococcus aureus infection. The antisense molecules and compositions comprise nucleic acid molecules, such as RNA, DNA, or nucleic acid molecules with modified backbones, such as PNA. The antisense molecules and compositions inhibit gene expression in Staphylococcus aureus; are optionally conjugated to cell penetration molecules such as peptides; and are optionally administered in the form of a nanoparticle composition.
    Type: Application
    Filed: March 14, 2014
    Publication date: June 23, 2016
    Applicant: Techulon Inc.
    Inventors: Brett MALONE, Joshua BRYSON
  • Publication number: 20160038528
    Abstract: The invention relates to rapidly adaptable nanotherapeutics. The therapeutics are nucleic acid molecules, such as, RNA, DNA, or modified-DNA. The nucleic acid therapeutics are preferably administered as a nanoparticle composition, further containing one or more synthetic polymers. The therapeutics are rapidly adaptable because the identification and design of the polynucleotide sequence containing the therapeutic sequence is based upon rapid computer-implemented bioinformatics and nucleic acid synthesis protocols. The rapid adaptable protocols differ from traditional methods of antibiotic and antipathogenic drug development, which are slow and do not address drug resistance issues. Furthermore, the invention encompasses a facility with dedicated apparatus for practicing the invention in military theater or where emerging pathogenic threats are located. This facility may be mobile and transportable as a dedicated unit.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Applicant: Techulon Inc.
    Inventors: Brett MALONE, Joshua BRYSON